A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
To determine the RP2D for FT516 as monotherapy (r/r AML), and in combination with rituximab or obinutuzumab (r/r B-cell lymphoma) To evaluate the safety and tolerability of FT516 as monotherapy following CY/FLU conditioning (r/r AML), and in combination with rituximab or obinutuzumab following CY/FLU conditioning (r/r B-cell lymphoma) To evaluate the safety and tolerability of FT516 in combination with rituximab or obinutuzumab following bendamustine conditioning (r/r B-cell lymphoma)
This Study is
No Longer Enrolling
Adult
Treatment
University of Colorado Hospital
Protocol Number: 21-3986
More information available at ClinicalTrials.gov: NCT04023071
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers